Stephen Crawford

Stephen Crawford

Auto-generated profile, based on publicly available information

Stephen Crawford

Takeda Development Center Americas, Inc , Cambridge, MA

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2026 in SLEEP Advances
Verified
Journal Article
Open access
SGSomraj Ghosh
Somraj Ghosh
VHVeena Hoffman
Veena Hoffman
BCBrian Calingaert
Brian Calingaert
DPDavid T Plante
David T Plante
LKLois E Krahn
Lois E Krahn
SCStephen Crawford
Stephen Crawford
Study Objectives: Narcolepsy is a chronic condition affecting the sleep/wake cycle that is challenging to diagnose. Epidemiological data from large US-focused studies remain limited, with no validated claims-based case selection definitions for narcolepsy. We estimated the prevalence/incidence of diagnosed narcolepsy (type 1 [NT1], type 2 [NT2], overall) in an insured US population using validated, claims-based narcolepsy case definitions. Materials and Methods: This observational study used HealthVerity administrative claims-linked electronic medical records to develop case definitions identifying individuals with NT1, NT2, and overall narcolepsy from diagnosis, medication, and procedure codes. Claims-based case definition performance (NT1, NT2, overall narcolepsy) was assessed using positive predictive values (PPVs). Prevalence (per 100 000 persons, on December 31, 2023) and annual incidence (per 100 000 person-years [PY], 2020 − 2023) were calculated/adjusted using PPVs for each case definition. Results: Unadjusted point prevalence among individuals with ≥12 months of continuous enrollment were 15.5/100 000 (NT1), 51.1/100 000 (NT2), and 67.0/100 000 (overall narcolepsy). Unadjusted incidence rates were stable from 2020 − 2023 for NT1 (range, 2.0 − 2.3/100 000 PY) but declined across years for NT2 (9.1 − 7.6/100 000 PY) and overall narcolepsy (11.3 − 9.6/100 000 PY). PPVs (95% confidence interval) of NT1, NT2, and overall narcolepsy were 0.81 (0.72 − 0.88), 0.84 (0.75 − 0.91), and 0.80 (0.71 − 0.87), contributing to epidemiologic estimates being reduced by ~20% after PPV adjustment. Prevalence and incidence were higher in females than males. Individuals with NT1 were ~ 4 years younger versus NT2. Conclusions: Validated definitions for narcolepsy can reduce potential misclassification. Our findings highlight a relatively low NT1 prevalence in the US. In contrast, NT2 prevalence estimates were > 3 times higher than NT1.

8 July 2026 in SLEEP Advances
Verified
Journal Article
Open access
SGSomraj Ghosh
Somraj Ghosh
SCStephen Crawford
Stephen Crawford
SBSarah L Bermingham
Sarah L Bermingham
MZMiriam L Zichlin
Miriam L Zichlin
FSFiona Stewart
Fiona Stewart
KKKristin Kistler
Kristin Kistler
The symptoms experienced by people with narcolepsy and idiopathic hypersomnia (IH) have profound effects on individuals’ lives, affecting daily functioning, relationships and mental health, and can impair performance at work or school. Although numerous studies have evaluated the impact of narcolepsy and IH on work-related outcomes, the evidence base is highly fragmented and difficult to meaningfully summarize. We conducted a systematic literature review of published evidence to better understand the impact of these disorders on employment, work productivity, work satisfaction, and related outcomes. We identified 54 publications representing 51 unique studies that met the study inclusion criteria and were included in the review. Although most people with narcolepsy or IH were employed, fewer were in paid work than control populations, and absenteeism and presenteeism were high. Having narcolepsy and IH resulted in lower wages and missed work time, leading to unfavorable impacts on career progression, promotion, job satisfaction, and income. The most frequently reported work-related problems were sleepiness at work, reduced performance, work accidents, and lateness. More severe excessive daytime sleepiness was associated with greater work impairment. Narcolepsy-specific medications that improved excessive daytime sleepiness were reported to improve work productivity in clinical trials; however, many people are left with substantial residual impairment despite treatment. These findings indicate that narcolepsy and IH impose a substantial burden on work functioning and employment, and there is a need for more research to inform interventions and policies aimed at mitigating the impact of these debilitating conditions on individuals’ professional lives.